Researchers at Tel Aviv University have achieved a breakthrough in drug delivery: they have successfully transported lipid ...

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

If the results from the clinical development plans are positive, it may well reflect a paradigm shift for clinical care.

In a large cohort of patients with autoimmune diseases, treatment with biologic disease-modifying antirheumatic drugs was ...

New research reveals a significant reduction in Parkinson’s disease risk among autoimmune patients treated with anti-TNF or ...

Scientists have found an unlikely anti-aging drug in the form of an anti-inflammatory drug that is designed to inhibit an inflammatory molecule known as interleukin-11 (IL-11). The drug was found ...

Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6 ... or disease-modifying antirheumatic drugs. A large clinical trial is needed ...

Humans inherited the protein, called interleukin-11 ... the 'dramatic' results were seen when they injected an anti-IL-11 drug, which stopped the protein from causing age-related effects in ...

"Everything injected into the bloodstream is eventually ends up in the liver — that's just how our anatomy works," Professor ...